BergenstalRM, KerrM, RobertsGJ, et al.Flash CGM is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes. J Endocr Soc, 2021; 5: bvab013.
2.
TangS, ShaoH, and ZhangP. Recommended and prevalent use of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter-2 inhibitors in a national population-based sample. Ann Intern Med, 2023; 176; 582–583.
3.
MarsoSP, McGuireDK, ZinmanB, et al.Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med, 2017; 377: 723–732.
4.
Diabetes Control and Complications Trial Research Group; NathanDM, GenuthS, LachinJ, et al.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329: 977–986.
5.
PathakS, KearinK, KahkoskaAR, et al.Impact of expanding access to continuous glucose monitoring systems among insulin users with type 1 or type 2 diabetes. Diabetes Technol Ther, 2023; 25: 169–177.
6.
MartensT, BeckRW, BaileyR, et al.Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA, 2021; 325: 2262–2272.
7.
ElSayedNA, AleppoG, ArodaVR, et al.on behalf of the American Diabetes Association. 7. Diabetes technology: standards of care in diabetes—2023. Diabetes Care, 2023; 46 (Suppl 1): S111–S127.
8.
GrantRW, HuangES, WexlerDJ, et al.Patients who self-monitor blood glucose and their unused testing results. Am J Manag Care, 2015; 21: e119–129.
9.
MalandaUL, WelschenLM, RiphagenII, et al.Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev, 2012; 1: CD005060.
10.
DavisGM, PetersAL, BodeBW, et al.Safety and efficacy of the Omnipod 5 automated insulin delivery system in adults with type 2 diabetes: from injections to hybrid closed-loop therapy. Diabetes Care, 2023; 46: 742–750.
11.
DaviesMJ, ArodaVR, CollinsBS, et al.Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2022; 45: 2753–2786.
12.
StellefsonM, DipnarineK, and StopkaC.The chronic care model and diabetes management in US primary care settings: a systematic review. Prev Chronic Dis, 2013; 10: E26.
13.
PageMJ, McKenzieJE, BossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021; 372: n71.
